Preclinical Evaluation of Esomeprazole Safety and Toxicokinetics

Preclinical Evaluation of Esomeprazole Safety and Toxicokinetics

Esomeprazole, the S-isomer of omeprazole, is a second-generation proton pump inhibitor widely used for acid-related diseases of the oesophagus, stomach, and duodenum (peptic ulcer, gastro-oesophageal reflux disease, etc.). Studies on esomeprazole safety and toxicokinetics (TK) are essential for incr...

Full description

Bibliographic Details
Main Authors:	V. M. Kosman, M. V. Karlina, E. V. Mazukina, A. A. Globenko, E. A. Jain, M. N. Makarova, V. G. Makarov
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2023-06-01
Series:	Безопасность и риск фармакотерапии
Subjects:	esomeprazole nexium proton pump inhibitors safety toxicokinetics preclinical studies
Online Access:	https://www.risksafety.ru/jour/article/view/342

Similar Items

EVALUATION OF PSORIASIS TREATMENT WITH ESOMEPRAZOLE - A PILOT STUDY
by: Mauro BAFUTTO, et al.

Esomeprazole-induced lichen planus
by: Miguel Santos-Coelho, et al.
Published: (2023-04-01)

Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs
by: Cook EK, et al.
Published: (2016-08-01)

Esomeprazole: a Safe Alternative to Lansoprazole Allergy?
by: Muammer Kara, et al.
Published: (2014-08-01)

The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study
by: Jae Kyu Sung, et al.
Published: (2016-12-01)

Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection
by: Young Dal Lee, et al.
Published: (2020-09-01)

Esomeprasol in the treatment of duodenal ulcer under various regimens of antihelicobacter therapy
by: I V Maev, et al.
Published: (2003-02-01)

Mandibular Osteonecrosis Associated with Antacid Therapy (Esomeprazole)
by: Simone Marconcini, et al.
Published: (2019-10-01)

Persistent cutaneous lesion in a child with tyrosinemia: Esomeprazole‐induced lichenoid drug eruptions
by: Bahareh Abtahi‐Naeini, et al.
Published: (2021-08-01)

Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study
by: Hyun Lim, et al.
Published: (2023-12-01)

In vitro comparative quality evaluation of different brands of esomeprazole tablets available in selected community pharmacies in Dhaka, Bangladesh
by: Oby dulla, et al.
Published: (2018-03-01)

Pharmacokinetics of esomeprazole in goats (Capra aegagrus hircus) after intravenous and subcutaneous administration
by: Rachel Fladung, et al.
Published: (2022-12-01)

Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole Avaliação clínica e endoscópica da doença do refluxo gastroesofágico em pacientes tratados com esomeprazol
by: Edson Pedro da Silva, et al.
Published: (2003-12-01)

Therapeutic Response to 20 mg of Esomeprazole Twice Daily in Patients with Gastroesophageal Reflux Disease-related Non-cardiac Chest Pain: An Open-Label Randomized Pilot Study
by: Jae Kyun Choi, et al.
Published: (2020-06-01)

Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer
by: G.D. Marijn Veerman, et al.
Published: (2022-11-01)

Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells
by: Livia Delpiano, et al.
Published: (2018-12-01)

Comparative analysis of the effect of PO administered acid suppressants on gastric pH in healthy cats
by: Phillip Ryan, et al.
Published: (2020-09-01)

Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
by: Yoshimasa Saito, et al.
Published: (2019-01-01)

A TRANSIENT DRUG INDUCED LUPUS ERYTHEMATOSUS- LIKE ALLERGIC DRUG REACTION WITH MULTIPLE ANTIBODIES
by: Ana Maria Abreu Velez, et al.
Published: (2013-10-01)

Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats
by: S. M. J AL-Hadrawy, et al.
Published: (2021-10-01)

Preparation and Characterization of Controlled-Release Floating Bilayer Tablets of Esomeprazole and Clarithromycin
by: Muhammad Israr, et al.
Published: (2022-05-01)

Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease
by: Natasha de Alwis, et al.
Published: (2022-08-01)

The toxicokinetic profile of Dex40-GTMAC3 - a novel polysaccharide candidate for reversal of unfractionated heparin.
by: Emilia eSokolowska, et al.
Published: (2016-03-01)

Pregnancy-specific physiologically-based toxicokinetic models for bisphenol A and bisphenol S
by: Jeremy Gingrich, et al.
Published: (2021-02-01)

Toxicokinetics of Zearalenone following Oral Administration in Female Dezhou Donkeys
by: Honglei Qu, et al.
Published: (2024-01-01)

Longitudinal study of gastroesophageal reflux and erosive tooth wear
by: Clive H. Wilder-Smith, et al.
Published: (2017-10-01)

Development, In-Vitro Characterization and Preclinical Evaluation of Esomeprazole-Encapsulated Proniosomal Formulation for the Enhancement of Anti-Ulcer Activity
by: Dibyalochan Mohanty, et al.
Published: (2022-04-01)

Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats
by: Tae Hwan Kim, et al.
Published: (2018-09-01)

Microcystin Toxicokinetics, Molecular Toxicology, and Pathophysiology in Preclinical Rodent Models and Humans
by: Tarana Arman, et al.
Published: (2021-07-01)

Influence of the Impregnation Technique on the Release of Esomeprazole from Various Bioaerogels
by: Milica Pantić, et al.
Published: (2021-06-01)

Development and validation of a high-performance liquid chromatography method for the estimation of esomeprazole in bulk and tablet dosage form
by: Trushal V Chorage, et al.
Published: (2023-11-01)

Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
by: Mingxing HOU, et al.
Published: (2020-11-01)

Stereoselective Toxicokinetic and Distribution Study on the Hexaconazole Enantiomers in Mice
by: Guofei Luo, et al.
Published: (2023-02-01)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
by: Ali Jaber, et al.
Published: (2022-10-01)

Preclinical Study of the Efficacy and Safety of Chondroitin Sulfate
by: E. V. Mazukina, et al.
Published: (2021-03-01)

A Scoping Assessment of Implemented Toxicokinetic Models of Per- and Polyfluoro-Alkyl Substances, with a Focus on One-Compartment Models
by: Alexander East, et al.
Published: (2023-02-01)

Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease
by: Hye Kyung Jeon, et al.
Published: (2022-04-01)

Toxicokinetics of a Single Oral Dose of OTA on Dezhou Male Donkeys
by: Ruifen Kang, et al.
Published: (2023-01-01)

Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia
by: Natasha de Alwis, et al.
Published: (2022-07-01)